Molecular Mechanisms of Human Papillomavirus-Induced Carcinogenesis

被引:89
作者
Lehoux, Michael
D'Abramo, Claudia M.
Archambault, Jacques [1 ]
机构
[1] Univ Montreal, Mol Virol Lab, Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada
基金
加拿大健康研究院;
关键词
Human papillomavirus; Cervical cancer; Genomic instability; Oncogenesis; Viral oncogenes; TYPE-16; E7; ONCOPROTEIN; E6 PROTEIN BINDS; TUMOR-SUPPRESSOR PROTEIN; SQUAMOUS-CELL CARCINOMAS; FOCAL ADHESION PROTEIN; FANCONI-ANEMIA; CERVICAL-CARCINOMA; TELOMERASE ACTIVITY; DNA-REPLICATION; P53; PROTEIN;
D O I
10.1159/000214918
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Approximately 20% of all cancers are associated with infectious agents. Among them, human papillomaviruses (HPVs) are very common and are now recognized as the etiological agent of cervical cancer, the second most common cancer in women worldwide, and they are increasingly linked with other forms of dysplasia. Carcinogenesis is a complex and multistep process requiring the acquisition of several genetic and/or epigenetic alterations. HPV-induced neoplasia, however, is in part mediated by the intrinsic functions of the viral proteins. In order to replicate its genome, HPV modulates the cell cycle, while deploying mechanisms to escape the host immune response, cellular senescence and apoptosis. As such, HPV infection leads directly and indirectly to genomic instability, further favouring transforming genetic events and progression to malignancy. This review aims to summarize our current understanding of the molecular mechanisms exploited by HPV to induce neoplasia, with an emphasis on the role of the 2 viral oncoproteins E6 and E7. Greater understanding of the role of HPV proteins in these processes will ultimately aid in the development of antiviral therapies, as well as unravel general mechanisms of oncogenesis. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:268 / 280
页数:13
相关论文
共 174 条
[1]   Ha-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix [J].
Alonio, LV ;
Picconi, MA ;
Dalbert, D ;
Mural, J ;
Bartt, O ;
Bazán, G ;
Dominguez, M ;
Teyssié, AR .
JOURNAL OF CLINICAL VIROLOGY, 2003, 27 (03) :263-269
[2]   E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I [J].
Ashrafi, GH ;
Haghshenas, MR ;
Marchetti, B ;
O'Brien, PM ;
Campo, MS .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (02) :276-283
[3]   STRUCTURAL AND TRANSCRIPTIONAL ANALYSIS OF HUMAN PAPILLOMAVIRUS TYPE-16 SEQUENCES IN CERVICAL-CARCINOMA CELL-LINES [J].
BAKER, CC ;
PHELPS, WC ;
LINDGREN, V ;
BRAUN, MJ ;
GONDA, MA ;
HOWLEY, PM .
JOURNAL OF VIROLOGY, 1987, 61 (04) :962-971
[4]   LOSS OF P53 PROTEIN IN HUMAN PAPILLOMAVIRUS TYPE-16 E6-IMMORTALIZED HUMAN MAMMARY EPITHELIAL-CELLS [J].
BAND, V ;
DECAPRIO, JA ;
DELMOLINO, L ;
KULESA, V ;
SAGER, R .
JOURNAL OF VIROLOGY, 1991, 65 (12) :6671-6676
[5]   The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-α [J].
Barnard, P ;
Payne, E ;
McMillan, NAJ .
VIROLOGY, 2000, 277 (02) :411-419
[6]   The epidemiology of human papillomavirus infections [J].
Baseman, JG ;
Koutsky, LA .
JOURNAL OF CLINICAL VIROLOGY, 2005, 32 :S16-S24
[7]   Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells [J].
BeerRomero, P ;
Glass, S ;
Rolfe, M .
ONCOGENE, 1997, 14 (05) :595-602
[8]   No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients [J].
Böhmer, G ;
van den Brule, AJC ;
Brummer, O ;
Meijer, CJLM ;
Petry, KU .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (01) :118-120
[9]   The causal relation between human papillomavirus and cervical cancer [J].
Bosch, FX ;
Lorincz, A ;
Muñoz, N ;
Meijer, CJLM ;
Shah, KV .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265
[10]   Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells [J].
Bousarghin, L ;
Touzé, A ;
Sizaret, PY ;
Coursaget, P .
JOURNAL OF VIROLOGY, 2003, 77 (06) :3846-3850